Loading
A phase 3 trial of Fulvestrant and Capivasertib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain is a phase 3 interventional study registered as NCT06764186 by AstraZeneca, with 101 participants enrolled, started 2025-01-07 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fulvestrant and Capivasertib.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.